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Description
[0001] The present invention relates to killing cells, or
at least impeding cell cycle progression. More particularly
it relates to methods and means for attacking eukaryotic
cells, such as tumour cells, with cytostatic, cytotoxic
and/or cytopathic agents. Specifically, the present inven-
tion employs the ParD kid toxin and ParD kis antitoxin
under appropriate control for selective cell cycle inhibition
and/or killing of target cells.
[0002] There are various contexts in which it is desired
to kill cells, in particular selectively to kill certain cells
within a population of cells. In some contexts inhibition
of cellular growth or proliferation, for instance by imped-
ing cell cycle progression, may be sufficient. For simplic-
ity herein, unless context provides otherwise, reference
to killing cells may be used to encompass such inhibition.
[0003] An important area of application is in treatment
of tumours, cancer, psoriasis, arteriosclerosis and other
hyper-proliferative disorders. Other applications of em-
bodiments of the present invention include targeting any
desired eukaryotic cell for killing or at least inhibition of
growth. This may include cell lineage knock-outs and tar-
geted cell ablation, for instance in developmental control,
or organogenesis studies. In vitro applications include
study of the control or replication in prokaryotic and/or
eukaryotic cells, screening for an antidote for a toxin, or
toxin inhibited by an antidote, design of or screening for
improved toxin and/or antidote factors, and analysis of
physiological responses of different cell types to inhibition
of cell progression and/or inhibition of DNA replication.
[0004] In plants, pathogen defence responses involve
cell necrosis, for instance triggered at a site of pathogen
infection or ingress. Induced resistance is strongly cor-
related with the hypersensitive response (HR), an in-
duced response associated with localized cell death at
sites of attempted pathogen ingress. It is hypothesized
that by HR the plant deprives the pathogen of living host
cells.
[0005] Many plant defence mechanisms are strongly
induced in response to a challenge by an unsuccessful
pathogen. Such an induction of enhanced resistance can
be systemic. It is believed that when a plant is challenged
by a pathogen to which it is resistant, it undergoes an HR
at the site of attempted ingress of the incompatible path-
ogen. The induced HR leads to a systemic enhancement
and acquisition of plant resistance to virulent pathogens
that would normally cause disease in the unchallenged
plant.
[0006] Artificial induction of cell death in plants has
been shown to be able to provide pathogen resistance,
even where the mechanism inducing cell death is not
triggered by any pathogen resistance gene. For instance,
genes coding for substances leading to rapid cell death,
such as BARNASE or diphtheria toxin may be use to
induce the changes that lead to acquired resistance even
though cell death in these latter examples is not caused
by activation of the defence response. BARNASE is a
ribonuclease from Bacillus amyloliquifaciens (Hartley
(1988) J. Mol. Biol. 202: 913-915; Hartley (1989) Trends
Biochem. Sci. 14: 450-454) and there is a corresponding
protein called BARSTAR which inhibits BARNASE by
forming a complex with it.
[0007] Use of embodiments of the present invention in
plants may be used to generate protection against attack
from fungi, bacteria, viruses or nematodes.
[0008] Plants of particular interest for use in embodi-
ments of the present include cereals, maize, corn, wheat,
barley, oats, rice, Brassicas, curcubits, potatoes, toma-
toes, cotton, soya bean, and carrot.
[0009] Another use of embodiments of the present in-
vention in plants include generation of male sterility(Mar-
iani et al. Nature 357 384-387). For instance toxin or a
toxin system in accordance with the present invention
may be introduced into plants under appropriate control
for tapetal-specific expression (Seurinck et al. (1990) Nu-
cleic Acids Res. 18: 3403; Koltunow et al. (1990) Plant
Cell 2, 1201-1224; Mariani et al (1990) Nature 347:
737-741). Male sterility in plants facilitates hybrid seed
generation by preventing self- pollination, allowing agri-
culturalists to take advantage of so-called "hybrid vigour"
by which crosses between inbred plant lines often result
in progeny with higher yield and increased resistance to
disease. Provision of horticultural or ornamental plants
lacking ability to make pollen may be used to reduce al-
lergy problems of local inhabitants or for aesthetic rea-
sons (e.g. in lilies, where anthers are currently removed
by hand).
[0010] A further use in plants is in generation of seed-
lessness, often desirable for convenience and taste in
produce such as watermelons, grapes, oranges and re-
lated fruits, tomatoes, peppers, cucumbers and so on.
Toxin can be placed under regulatory control of a seed-
specific promoter, such as the promoter of a seed storage
protein (Higgins et al, (1984) Ann. Rev. Plant. Physiol.
35: 191-221; Goldberg et al (1989) Cell 56: 149-160).
Examples of seed-specific promoters include those for
bean β-phaseolin (Sengupta-Gopalan et al, (1985)
PNAS US 82: 3320-3324), bean lectin (Voelker et al
(1987) EMBO J. 6: 3571-3577), soybean lectin (Ocamuro
et al. (1986) PNAS USA 83: 8240-8344), rapeseed napin
(Radke et al. Theor. Appl. Genet. 75: 685-694), maize
zein (Hoffman et al (1987) EMBO J. 6: 3213-3221), barley
β-hordein (Marris et al (1988) Plant Mol. Biol. 10:
359-366) and wheat glutenin (Colot et al. (1987) EMBO
J. 6: 3559-3564).
[0011] Prokaryotic plasmids have developed different
genetic systems that increase their stable maintenance
in bacterial hosts. These systems are classified into two
different types: partition systems, that ensure a well con-
trolled partition of plasmid DNA copies between the two
daughter cells, and killer systems, that eliminate from the
bacterial population those daughter cells that have lost
the plasmid during division (Yarmolinsky, Science (1995)
Feb 10,267 (5199): 836-7). The latter are composed of
two components: a bacterial toxin (always a protein), and
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its antidote (a protein or an antisense RNA that inhibits
transcription of its killer partner) (Jensen and Gerdes,
Mol. Microbiol. (1995) Jul. 17 (2): 205-10; Thisted et al.
J. Mol. Biol. (1992). Jan. 5 223 (1): 41-54). These killer
systems are generally organized similarly from a molec-
ular point of view, and several mechanisms ensure that
a typical killer system is not activated if the stability of its
harbouring plasmid is not compromised. Thus, both pro-
teic antidote and toxic components are organized in a
bicistronic operon, and the system is molecularly de-
signed in such a way that both transcriptional and trans-
lational processes are optimised to maintain it in a silent
state (i.e. a state in which the toxic component is being
neutralised by its antidote) (Jensen and Gerdes, Mol.
Microbiol. (1995) Jul 17(2): 205-10; Holcik and Iyer,
Microbiology (1997), 143: 3403-3416).
[0012] Under normal circumstances, both compo-
nents of a killer system are synthesized at a basal level
in the host by its harbouring plasmid, allowing the host
to survive. If a segregant bacteria (i.e. a bacteria that has
lost the plasmid) appears after cell division, another char-
acteristic of these systems allows activation of the killing
process in order to counter-select that specific cell: that
is, the stability of the antidote is lower than the toxin.
Thus, without a continuous synthesis of the antidote, its
preferential degradation leads to the appearance of a
non-neutralised toxin that is then able to exert its lethal
effect over the host. This toxic effect can be executed
affecting different cellular targets, depending on the spe-
cific killer system, for example DnaB dependent replica-
tion (parD, pem), DNA-gyrase complex (ccd), protein
synthesis inhibition (KicB), and septum formation (kil),
(for references see Holcik and Iyer, Microbiology (1997),
143, 3403-3416). Yarmolinsky describes in Science, Vol.
267 (1995) other putative "addiction molecules" like the
type II restriction enzymes (putative toxins) Pae R7 and
EcoRI and their cognate methylases, that enhance the
apparent stability of their harbouring plasmids (the orig-
inal reference for this addiction modules is in Naito et al.
Science 267: 897 (1995)). In this work, Yarmolinsky also
describes a couple of putative killer systems from bacte-
riophage lambda (Rex protein) and a couple of strains of
E. coli carrying the gene cluster prr, that encodes for an
anticodon nuclease that can be activated by a 26 residue
polypeptide from bacteriophage T4 and can then cleave
a transfer RNA important for lysine incorporation into pro-
teins. T4 is invulnerable to this protein because it encodes
for a couple of otherwise non-essential proteins that un-
does the damage. He also describes strains of E. coli
that carry defective prophage e14, and that accomplish
exclusion by cleavage of elongation factor Tu and inhib-
iting translation globally.
[0013] ParD is one of these killer systems (Bravo et al.
Mol. Gen. Genet. (1987) Nov. 210(1): 101-10; Bravo et
al. Mol. Gen. Genet. (1988). Dec. 215 (1): 146-51). It is
encoded by Gram negative plasmid R1 and is composed
of two genes: kis (for killing suppressor) and kid (for killing
determinant) that encode for the antidote (10 KDa) and
the toxin (12 KDa) respectively. ParD is a cryptic killer
system that is tightly regulated to avoid its activation un-
der circumstances that do not compromise R1 stability.
Thus, it is controlled by coupled transcription (Ruiz-Eche-
varria et al. Mol. Microbiol. (1991) Nov. 5 (11): 2685-93),
by post- transcriptional processing of its bicistronic mRNA
(Ruiz-Echevarria et al. Mol. Gen. Genet. (1995) Sep. 20
248(5): 599-609), by overlapped translation (Ruiz- Eche-
varria et al. Mol. Gen. Genet. (1995) Sep. 20 248(5):
599-609), and by a very tight interaction between Kis and
Kid to form a non-toxic complex that, at the same time,
is able to repress transcription from its own promoter
(Ruiz-Echevarria et al. Mol. Microbiol. (1991) Nov. 5(11):
2685-93). Genetic organisation of ParD favours coupled
transcription, overlapped translation and post-transcrip-
tional modification of some of the obtained mRNA.
Kis/Kid complexes repress transcription of kis and kid
genes.
[0014] ParD homologues have been described at least
in plasmid R100 (pem system) (Tsuchimoto et al. J. Bac-
teriol. (1988) Apr. 170 (4): 1461-6; Tsuchimoto et al. J.
Bacteriol. (1992) Jul. 174 (13): 4205-11; Tsuchimoto et
al. Mol. Gen. Genet. (1993) Feb. 237(1-2): 81-88); Mas-
uda et al. J. Bacteriol. (1993) Nov. 175 (21): 6850-6) and
in E. coli chromosome (ChpA and ChpB systems)
(Tsuchimoto et al. Mol. Gen. Genet. (1993) Feb. 237
(1-2): 81-88). Others are revealed by database search-
ing.
[0015] Kid inhibits initiation of replication of the E. coli
genome and of DnaB (i.e. the main replicative helicase
of E. coli) dependent replication plasmids (Ruiz-Echev-
arria et al. J. Mol. Biol. (1995) Apr. 7 247 (4): 568-77), and
over- expression of the latter titrates the toxic effect of the
former in this organism in vivo (Ruiz-Echevarria et al. J.
Mol. Biol. (1995) Apr. 7 247(4): 568-77), suggesting that
DnaB is involved in the mechanism of inhibition by Kid.
Recent observations in the inventors’ laboratory strongly
suggest that this inhibition is due neither to disassembly
by Kid of DnaB hexameric complexes in solution nor to
inhibition of its helicase activity over a wide range of sub-
strates including oriC, the replication origin of the E. coli
genome. Without wishing to be limited by theory, it may
be that loading of DnaB at the origin of replication is the
process inhibited by Kid, either by direct interaction be-
tween them and/or mediated by a third component (DNA
or protein) yet to be described. Current research is fo-
cused on the identification of the exact mechanism of
action of Kid from a molecular point of view.
[0016] Until the work of the present inventors disclosed
herein it was not obvious that prokaryotic systems that
have evolved for specific roles in bacteria could function
in eukaryotic cells.
[0017] For instance, in a two-component killer system
such as involving kis/ kid, both components need to per-
form their respective functions - the toxin to kill cells in
the absence of antidote (or when present in excess of
antidote), and the antidote to.both neutralise the toxin
and be controllable, for instance by a mechanism involv-
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ing rapid turnover. Preferably the toxin does not exert
any side effect on cell viability. Rather, it is preferred that
cell killing is via a programmed cell death mechanism
such as apoptosis. In plants it may be preferred for certain
applications to induce a necrotic response, e.g. in induc-
ing or enhancing pathogen resistance.
[0018] The present inventors have shown that bacte-
rial toxin and antidote are functional in eukaryotic cells,
yeast, Xenopus and mammalian (in particular human),
and can be controlled to inhibit cell cycle progression and
cellular proliferation and to kill cells. It is shown in exper-
iments described below that cells can be killed by apop-
tosis.
Brief Description of the Figures
[0019]
Figure 1 shows results of experiments showing that
a promoter induced by Curl later used for control of
Kis antidote expression and a different promoter re-
pressed by methionine later used for control of Kid
toxin expression are both functional in S. cerevisiae.
The graph shows units of β-galactosidase activity at
different concentrations (PM) of the regulatory fac-
tors Cu2+ (light circles) and Met (dark circles).
Figure 2 shows results of experiments demonstrat-
ing the effect of Doxycyclin on a Tetracyclin regulat-
able promoter (Tet Pr) activity in HeLa cells (light
bars), this promoter later used for control of expres-
sion of antidote Kis (in the vector pTRE-Luc), and an
absence of effect of Doxycyclin on Cytomegalovirus
Early promoter (CMV Pr) activity (dark bars), this pro-
moter later used for control of expression of toxin Kid
(pCMV- Luc). Luciferase activity is plotted, in arbi-
trary units.
Figure 3 illustrates various constructs employed for
expression of Kis and/or Kid in HeLa cells.
Figure 4 shows results of experiments in which kis
expression was modulated by Doxycyclin in cultures
of HeLa cells stably transfected with pNATHAli and
pNATHA2i (Figure 3). Kid expression was controlled
by CMV Pr which is unaffected by Doxycyclin.
Figure 5 shows further results of experiments (num-
bers of dead cells) in which kis expression was mod-
ulated by Doxycyclin in cultures of HeLa cells stably
transfected with pNATHAli and pNATHA2i (Figure
5). Kis expression was controlled by the Tet Pr which
is repressed by Doxycyclin, while kid expression was
controlled by CMV Pr which is unaffected by Doxy-
cyclin.
Figure 6 shows emergence of the apoptosis marker
Annexin V in cells subject to the experiments of which
results are shown in Figure 5, indicating the cell
death caused by Kid to involve apoptosis.
[0020] According to one aspect of the present inven-
tion there is provided a composition comprising:
(i) the ParD kid toxin and ParD kis antitoxin, or
(ii) nucleic acid encoding the ParD kid toxin and ParD
kis antitoxin,
for use in a therapeutic method of inhibiting cell prolifer-
ation and/or cell cycle progression carried out on a human
or animal body, the method comprising providing within
eukaryotic cells in the human or animal body the toxin
and antitoxin, under appropriate control for selective cell
cycle inhibition and/or killing of target cells.
[0021] According to a second aspect of the invention,
use of a composition comprising: 
(i) the ParD kid toxin and ParD kis antitoxin, or
(ii) nucleic acid encoding the ParD kid toxin and ParD
kis antitoxin,
in the manufacture of a medicament composition for
use in a therapeutic method of inhibiting cell prolif-
eration and/or cell cycle progression carried out on
a human or animal body, the method comprising pro-
viding within eukaryotic cells in the human or animal
body the toxin and antitoxin, under appropriate con-
trol for selective cell cycle inhibition and/or killing of
target cells.
[0022] A third aspect of the invention is a method of
inhibiting cell proliferation and/or cell cycle progression,
the method comprising providing within eukaryotic cells
the ParD kid toxin and ParD kis antitoxin under appro-
priate control for selective cell cycle inhibition and/or kill-
ing of target cells, wherein the cells are in vitro and/or
are plant cells.
[0023] Some measure of control of toxin action is pref-
erably employed in aspects of the present invention. Bac-
terial cell killing systems of use in the present invention
naturally employ the PaD kis antitoxin. The present in-
ventors have shown that both toxin and antitoxin are func-
tional in various eukaryotic cells and that their respective
activities can be controlled for selective inhibition of cel-
lular proliferation or impedance of cell cycle progression,
and/or induction of programmed cell death.
[0024] The bacterial cell killing system employed in the
present invention comprises a toxin and an antitoxin
which are both protein. Such a killing system is termed
in the art a "proteic killer gene system" - Jensen & Gerdes,
1995, Mol. Microbiol. (1995) Jul 17(2): 205-10). The bac-
terial killer system used in the invention is an E. coli sys-
tem.
[0025] Examples of bacterial killer systems (for refer-
ences see Holcik and Iyer (1997), Microbiology, 143:
3403-3416 and references therein, and "Horizontal Gene
Pool: Bacterial Plamids and Gene Spread" (1999), Ed.
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C M Thomas, Howard Academic Publishers, Chapter 2),
include a bacterial plasmid- borne proteic killer gene sys-
tem such as ParD (or R1 or homologues as discussed:
above) ccdA (H or let A) of the F plasmid (antidote) and
ccdB (G, letB or letD) toxin which acts by poisoning DNA-
gyrase complexes (Jaffé, et al. (1985), Bacteriol, 163:
841-849) note that the mode of action of the ParD system
is remarkably similar to that of the Ccd system), bacteri-
ophage P1 toxic protein Doc with antidote Phd (Lehnherr,
et al. (1993), Mol. Biol., 233: 414-428), parDE of plasmid
RK2 (Roberts et al., 1994 J. Mol. Biol. 268,
27109-27117), with toxic protein ParE and antidote ParD,
and hig of plasmid Rtsl (Tian et al., 1996, Biochem bio-
phys Res Commun 220 280-284) with antidote higA to
toxin higB.
[0026] Further examples of bacterial killer systems,
where the natural antidote is an antisense RNA inlcude
parB of plasmid R1 (Gerdes, et al,. (1990a), New Biol,
2: 946-956) with toxin Hok and antidote Sok (Thisted et
al, 1994, EMBO J. 13, 1950-1959; hok mRNA is very
stable but sok RNA decays rapidly), srnB (Onishi, (1975),
Science, 187: 257-258) flm (Loh, et al. (1988), Gene, 66:
259-268) of the F plasmid and pnd of both Incl plasmid
R483 and IncB plasmid R16 (Akimoto and Ohnishi
(1982), Microbiol. Immunol., 26: 779-793), relF of the E.
coli chromosomal relB operon (induction of the relF gene
leads to the same physiological response as expression
of the hok gene - Gerdes, et al. (1986a), EMBO J. 5:
2023-2029), relB homologues (Gronlund and Gerdes,
1999, J. Mol. Biol. 285, 1401-1415) and Gef (also chro-
mosomal) which is structurally and functionally similar to
the proteins encoded by hok and relF (Poulsen, et al.
(1989), Mol. Microbiol. , 3: 1463-1472). Gef protein is tox-
ic and regulated by antisense RNA Sof.
[0027] Further systems include SegB operon epsilon
(antidote) and zeta (toxin) of pSM19035 and pDB101
(Ceglowski et al. (1993) Mol. Gen. Genet. 241 (5-6) :
579-85; Ceglowski et al. (1993) Gene 136 (1-2) : 1-12),
kicA (antidote) and kicB (toxin) found in the E. coli chro-
mosome (Feng, et al. (1984), Mol. Gen. Genet., 243 :
136-147), and the kil/kor systems carried by bacterial
plasmids of the incompatibility groups P:and N. See Hol-
cik and Iyer (Microbiology (1997) 143: 3403-3416) for
examples and references. See also Jensen and Gerdes
(Mol. Microbiol. (1995) 17 (2), 205-210) and Yarmolinsky
(Science, (1995) 267, 836-837) for reviews of proteic kill-
er gene systems, noted to have striking similarities in
both structure and function.
[0028] The ParD Kid toxin is employed herein with the
respective antidote, the ParD kis antitoxin. Additionally,
the toxin may be employed with one or more other ele-
ments which inhibit or block its activity (which may be by
inhibiting or blocking its production) as discussed.
[0029] Both toxin and antidote are introduced into eu-
karyotic cells under appropriate control for selective cell
cycle inhibition and/or killing.
[0030] A method of the invention may include providing
ParD kid toxin and ParD kis antitoxin to eukaryotic cells
and, in target cells, removing or inhibiting the antitoxin to
allow the toxin to work. Production or activity of antitoxin
may be inhibited or blocked. This may be by provision of
an appropriate stimulus, e.g. inducer or repressor mole-
cule of a promoter controlling antitoxin production, or may
occur under conditions prevailing in target cells. As dis-
cussed below, the presence of a different form of a protein
such as p53 in target cells vs. non- target cells (e.g. for
p53 tumour and non-tumour cells) can be employed as
a controlling stimulus. An inducer or repressor molecule
may be delivered to target cells to inhbit or block antitoxin
and/or upregulate toxin.
[0031] Generally, the cell killing system is provided to
cells by means of nucleic acid encoding the relevant com-
ponents and, where applicable, control elements (dis-
cussed further below).
[0032] Control elements may include any one or more
of those available in the art allowing for selective variation
of the ratio of toxin versus antitoxin. Examples include
an inducible, repressible or constitutive promoter, anti-
sense constructs and their activator or repressors, ri-
bozymes,  splicing sequences and splicing factors, re-
combination systems (e.g. Cre-lox or FLP); wild-type or
modified Internal Ribosome Entry Sites (IRES) (Schmid
and Wimmer (1994), Arch. Virol. Suppl., 9: 279-89; Bor-
man, et al. (1994), EMBO J., 1:13 (13): 3149-57) and IRES
inhibitors such as a yeast RNA that inhibits entry of ri-
bosomes at some IRES (Das, et al. (1996), J. Virol., 70
(3): 1624-32; Das; et al. (1998), J. Virol., 72 (7): 6638-47;
Das, et al. (1998), Front Biosci., 1: 3: D1241-52; Venka-
tosan, et al. (1999), Nucleic Acids Res. 15: 27 (2):
562-72), elements that allow transcriptional interference
between promoters (Greger and Proudfoot (1998), 17:
17 (16) : 4771-9 ; Eggermont and Proudfoot (1993), EM-
BO J., 12(6): 2539.-48 ; Bateman and Paule (1998), Cell,
23:54(7): 985-92; Ponnambalam and Busby (1987),
FEBS Lett., 9:212 (1): 21-7; Greger, et al. (1998), Nucleic
Acids Res.,..1: 26 (5): 1294-301), inteins (Chong et al.
(1996) J. Biol Chem 271 (16) : 22159-68).
[0033] A eukaryotic vector may be provided, compris-
ing nucleic acid encoding a toxin or cell killing system,
as disclosed. Such a vector may be used to provide the
toxin or cell killing system to eukaryotic cells.
[0034] Nucleic acid encoding a bacterial toxin and an-
tidote may be provided as part of a vector or vectors
suitable for transformation of eukaryotic cells. Preferably
the vector is suitable for transformation of target cells,
for instance it may be suitable for transformation of plant
cells (e.g. an Agrobacterium vector). Where two compo-
nents of a bacterial killing system are employed, or a
toxin is employed and a specifically designed regulatory
element is employed (e.g. antisense or ribozyme), pref-
erably both components and regulatory elements for con-
trol of expression are provided on the same vector, but
may be provided on separate vectors. Either or both of
the encoding nucleotide sequences may be under tran-
scriptional control of a specific and/or regulatable pro-
moter. Toxin- and antidote- encoding sequences may be
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provided in a "tail-to-tail" or inverted orientation, or in a
head-to-tail orientation.
[0035] Advantageously, for example in yeast, nucleic
acid encoding toxin is provided on a multicopy plasmid,
such as, for yeasts 2P (Christianson, et al. (1992), Gene,
2: 110 (1) : 119-22), for mammalian cells a vector includ-
ing oriP from Epstein Barr Virus (that may be accompa-
nied by the initiator protein EBNA1 Kirchmaier and Sug-
den (1995), J. Virol., 69(2): 1280-3; Wendelburg and Vos
(1998), Gene Ther., Oct:5(10): 1389-99), or the origin
from the Bovine Papilloma Virus (that needs also two
virus encoded proteins to be active (Piirsoo, et al. (1996),
EMBO J., 2 : 15 (1) : 1-11), or a viral vector.
[0036] Monocopy vectors useful in the present inven-
tion include, for yeast, ARS1 and ARSH4/CEN6 (Sikorski
and Hieter (1986), Genetics, 122 (1): 19-27; Mumberg,
et al. (1995), Gene, 14: 156 (1): 119-22).
[0037] Suitable vectors can be chosen or constructed,
containing appropriate regulatory sequences, including-
promoter sequences, terminator fragments, polyade-
nylation sequences, enhancer sequences, marker genes
and other sequences as appropriate. Vectors may be
plasmidic and/or viral and maintained in cells as epi-
somes or integrated into the genome. For further details
see, for example, Molecular Cloning: a Laboratory Man-
ual: 2nd edition, Sambrook et al., 1989, Cold Spring Har-
bor Laboratory Press. Many known techniques and pro-
tocols for manipulation of nucleic’ acid, for example in
preparation of nucleic acid constructs, mutagenesis, se-
quencing, introduction of DNA into cells and gene ex-
pression, and analysis of proteins, are described in detail
in Short Protocols in Molecular Biology, Second Edition,
Ausubel et al. eds., John Wiley & Sons, 1992.
[0038] The ParD kid toxin and ParD kis antitoxin may
be provided in accordance with the present invention to
a eukaryotic cell selected from mammalian, human or
non-human such as rabbit, guinea pig, rat, mouse or oth-
er rodent, cat, dog, pig, sheep, goat, cattle or horse, bird,
such as a chicken, yeast, fungi, amphibian, fish, worm,
and plant Plants which may be employed in the present
invention have been noted already above.
[0039] A eukaryotic cell may be provided containing
nucleic acid encoding a bacterial toxin and/or antidote or
cell killing system as disclosed herein, under appropriate
regulatory control. The nucleic acid may be integrated
into the genome (e.g. chromosome) of the cell. Integra-
tion may be promoted by inclusion of sequences which
promote recombination with the genome, in accordance
with standard techniques. The nucleic acid may be on
an extra- chromosomal vector within the cell.
[0040] A method of the invention may include introduc-
ing the nucleic acid into a eukaryotic cell. The introduc-
tion, which may (particularly for in vitro introduction) be
generally referred to without limitation as "transforma-
tion", may employ any available technique. For eukary-
otic cells, suitable techniques may include calcium phos-
phate transfection, DEAE- Dextran, electroporation, lipo-
some-mediated transfection and transduction using ret-
rovirus or other virus, e.g. vaccinia or, for insect cells,
baculovirus.
[0041] The introduction may be followed by causing or
allowing expression from the nucleic acid, e.g. by cultur-
ing cells (which may include cells actually transformed
although more likely the cells will be descendants of the
transformed cells) under conditions for expression of one
or more components of the system, so that an encoded
product is produced. The conditions may provide for cell
killing (or inhibition of cell cycle progression, cell growth
or proliferation, etc.), and/or neutralisation of the toxic
effect when appropriate.
[0042] Introduction of nucleic acid may take place in
vivo by way of gene therapy, as discussed below. A cell
containing nucleic acid encoding a system according to
the present invention, e.g. as a result of introduction of
the nucleic acid into the cell or into an ancestor of the
cell and/or genetic alteration of the sequence endog-
enous to the cell or ancestor (which introduction or alter-
ation may take place in vivo or ex vivo), may be comprised
(e.g. in the soma) within an organism which is an animal,
particularly a mammal, which may be human or non-hu-
man, yeast, fungal, amphibian, fish, worm or plant, with
examples noted already above. Genetically modified or
transgenic animals, birds or plants comprising such a cell
may also be provided.
[0043] Thus, there may be provided a non-human an-
imal with nucleic acid encoding a bacterial cell killing sys-
tem (as disclosed) within its genome. The animal may
be rodent, e.g. mouse, and may provide an animal model
for investigating aspects of cell cycle control, cell killing,
apoptosis or other cellular process, and drug screening.
[0044] A plant with nucleic acid encoding a bacterial
cell killing- system within its genome, a plant cell (which
may be in culture, e.g. callus culture, or comprised in a
plant or plant part), or a plant part (e.g. fruit, leaf, seed
or other propagule) may also be provided.
[0045] For generation of plant material comprising nu-
cleic acid encoding a bacterial cell killing system as dis-
closed, any appropriate means of transformation may be
employed. Agrobacterium transformation is widely used
by those skilled in the art to transform both dicotyledo-
nous and monocotyledonous species. Microprojectile
bombardment, electroporation and direct DNA uptake
are preferred where Agrobacterium is inefficient or inef-
fective. Alternatively, a combination of different tech-
niques may be employed, e.g. bombardment with Agro-
bacterium coated microparticles or microprojectile bom-
bardment to induce wounding followed by cocultivation
with Agrobacterium. Following transformation, a plant
may be regenerated, e.g. from single cells, callus tissue
or leaf discs, as is standard in the art. Almost any plant
can be entirely regenerated from cells, tissues and or-
gans of the plant.
[0046] Where a bacterial cell killing toxin is employed
there are various strategies for controlling its activity.
Generally, the relevant antidote is employed to neutralise
the toxic effect unless and until the toxicity is desired.
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Thus, for example, both toxin and antidote may be ex-
pressed in normal cells, with antidote production being
down-regulated in target cells (e.g. tumour cells). Toxin
production may be down-regulated in normal cells and/or
upregulated in target cells. Antidote production may be
upregulated in normal cells and/or downregulated in tar-
get cells.
[0047] Upregulation of toxin and/or antidote produc-
tion, depending on context, may be achieved by a number
of means. A preferred approach is to employ a promoter
or other regulatory element that is inducible under certain
conditions, allowing for control of expression by means
of application of an appropriate stimulus.
[0048] A tumour specific promoter such as telomerase
RNA promoter may be employed. In plants nematode
inducible promoters such as TobRB7 (Opperman et al.,
Science 263: 221-223) and PRP1 (pathogenesis related
protein - see e.g. Payne et al. (1989) Plant Molecular
Biology 12: 595-596; also Memelink et al. (1990) Plant
Molecular Biology 14: 119-126 and Payne et al. (1990)
Proc. Natl. Acad. Sci. USA 87: 98-102) may be employed.
[0049] Downregulation of toxin and/or antidote, again
depending on context, may also be achieved by means
of regulation of gene expression using an appropriate
promoter or other regulatory element, including a repres-
sor element, such as Tet Pr. Other approaches which
may be employed include antisense regulation and ri-
bozymes (discussed further below).
[0050] Thus, for example, antidote production may be
downregulated by production of an antisense transcript
or ribozyme. The antisense transcript or ribozyme may
be produced on application of an appropriate stimulus,
and may be be produced by expression from a sequence
under transcriptional control of an inducible promoter or
other regulatory element.
[0051] By "promoter" is meant a sequence of nucle-
otides from which transcription may be initiated of DNA
operably linked downstream (i.e. in the 3’ direction on
the sense strand of double-stranded DNA).
[0052] "Operably linked" means joined as part of the
same nucleic acid molecule, suitably positioned and ori-
ented for transcription to be initiated from the promoter.
DNA operably linked to a promoter is "under transcrip-
tional initiation regulation" of the promoter.
[0053] The term "inducible" as applied to a promoter
is well understood by those skilled in the art. In essence,
expression under the control of an inducible promoter is
"switched on" or increased in response to an applied stim-
ulus (which may be generated within a cell or provided
exogenously). The nature of the stimulus varies between
promoters. Some inducible promoters cause little or un-
detectable levels of expression (or no expression) in the
absence of the appropriate stimulus. Other inducible pro-
moters cause detectable constitutive expression in the
absence of the stimulus. Whatever the level of expres-
sion is in the absence of the stimulus, expression from
any inducible promoter is increased in the presence of
the correct stimulus. The preferable situation is where
the level of expression increases upon application of the
relevant stimulus by an amount effective to provide the
desired result. Thus an inducible (or "switchable") pro-
moter may be used which causes a basic level of expres-
sion in the absence of the stimulus which level is too low
to bring about the desire result (and may in fact be zero).
Upon application of the stimulus, expression is increased
(or switched on) to a level which brings about the desired
result.
[0054] Examples of inducible-promoters for use in as-
pects of the present invention include a minimal promot-
er, such as CMV minimal promoter, fused to an enhancer
for wild- type p53 activation or mutant p53 repression
whether bearing the consensus DNA binding sequence
for wild- type p53, e.g. fragment A (Kern, et al. (1991),
Science, 252 (5013): 1708-11) or CON (Chen, et al.
(1993), Oncogene, 8(8): 2159-66), or not, e.g. HIV 1- LTR
(Subier, et al. (1994), J. Virol., 68(1): 103-10; Gualberto
and Baldwin (1995), J. Biol. Chem., 25: 270(34):
19680-3; Sawaya, et. al. (1998), J. Biol. Chem., 7: 273
(32): 20052-7, inducible or repressible promoters such
as Tet Pr as discussed and galactose activatable GAL10-
CYC1. For plants suitable promoters include the induci-
ble GST- II promoter from maize (Jepson et al. (1994).
Plant Molecular Biology 26:1855-1866), alcohol induci-
ble promoter (e.g. alcr - see e.g. Gatz (1998) Nature Bi-
otechnology 16: 140), and the Cauliflower Mosaic Virus
35S (CaMV 35S) gene promoter that is expressed at a
high level in virtually all plant tissues (Benfey et al, (1990)
EMBO J 9: 1677-1684).
[0055] As noted, toxin production may be downregu-
lated in non-target cells by employing elements for con-
trol of expression. Alternatively or additionally downreg-
ulation may employ antisense nucleic acid or ribozymes.
One or more of these approaches may be: employed in
addition to use of antitoxin to neutralise toxin activity.
Antitoxin production itself may be controlled, as dis-
cussed.
[0056] In a preferred approach selectivity for expres-
sion within target cells of the toxin in accordance with the
present invention is effected by a combination of (i) up-
regulation of toxin production in target cells and (ii)- down-
regulation of toxin production in non-target cells and/or
neutralisation of toxin activity in non-target cells (for in-
stance by upregulation of antidote production in non-tar-
get cells). Effect (i) will mediate the desired activity in
target cells, while effect (ii) will reduce the extent of
"leaky" expression of that activity in non-target cells.
[0057] Where target cells are tumour cells, and non-
target cells are normal cells, advantage can be taken of
the fact that p53 is mutated or its function inactivated in
a large proportion of tumours. The p53 protein is a tran-
scriptional activator in normal cells but is present in mu-
tant form in a substantial proportion (40-80%) of human
tumours. Even in tumours in which the p53 sequence is
wild- type, its normal function in cell cycle control, DNA
repair, differentiation, genome plasticity or apoptosis
may be abrogated, for instance by interaction with cellular
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protein (e.g. mdm2) or oncoviral protein (e.g. SV40 T
antigen, human papillomavirus E6 protein, adenovirus
E1B protein, hepatitis B virus X protein, and Epstein-Barr
BZLF-1 protein), or by being sequestered in the cyto-
plasm, where the p53 protein is non-functional.
[0058] Accordingly, production of the antidote (or an-
tisense RNA or a ribozyme directed against the toxin)
may be controlled by a promoter whose function is up-
regulated by wild-type p53 in normal cells but not by mu-
tant p53 in tumour cells. Wild-type p53 protein binds to
two copies of the consensus sequence 5’-PuPuPuC
(A/T) (A/T) GpyPyPy-3’ (SEQ ID NO. 1) and thereby
transactivates the level of transcription from an operably
linked promoter. Most of the mutations in the p53 gene
lead to abrogation of the sequence-specific transcription-
al activating function.
[0059] Production of the toxin may be controlled by a
promoter whose function is suppressed by wild-type p53
protein in normal cells, but is not suppressed or is even
upregulated by mutant p53 protein, e.g. hsp70 promoter,
mdm2 promoter and Others. See for example "The On-
cogene and Tumour Suppressor Gene Facts Book",
Robin Hesketh, Academic Press, Second Edition (1997)
Chapter p53, pages 446-463 and references therein.
[0060] The promoters of a number of cellular genes
are negatively regulated by wild- type p53, include basic
FGF (also activated by mutant p53), Bcl-2, human inter-
leukin 6 and PCNA. Again, see "The Oncogene and Tu-
mour Suppressor Gene Facts Book", Robin Hesketh, Ac-
ademic Press, Second Edition (1997) Chapter p53, pag-
es 446-463 and references therein for examples. Viral
promoters inhibited by wild-type p53 and in some cases
activated by mutant versions are referenced in Deb et al.
(1992) J. Virology, 66(10): 6164-6170.
[0061] Accordingly, such a promoter or a binding site
for wild-type p53 from such a promoter may be operably
linked to nucleic acid encoding the toxin. In normal cells,
wild- type p53 protein suppresses production of the toxin.
However, in tumours where p53 is not functional and
does not bind its binding site in the promoter, toxin pro-
duction is derepressed.
[0062] Similarly, a response element which is activat-
ed by mutant p53 but not wildtype, such as from HIV1-
LTR DNA sequences, may be employed to provide for
upregulation of toxin in tumour cells, or downregulation
of antidote where a third component is employed to con-
trol antidote production in tumour cells. An element acti-
vated by mutant p53 element (for example) may by used
to upregulate an antisense RNA, ribozyme or other factor
which downregulates antidote production in tumour cells.
[0063] In non-target cells production of toxin may be
inhibited by using appropriate nucleic acid to influence
expression by antisense regulation. Such approaches
may be used to downregulate antidote production in tar-
get cells. The use of anti-sense genes or partial gene
sequences to down- regulate gene expression is now
well-established. Double- stranded DNA is placed under
the control of a promoter in a "reverse orientation" such
that transcription of the "anti-sense" strand of the DNA
yields RNA which is complementary to normal mRNA
transcribed from the "sense" strand of the target gene.
The complementary anti-sense RNA sequence is
thought then to bind with mRNA to form a duplex, inhib-
iting translation of the endogenous mRNA from the target
gene into protein. Whether or not this is the actual mode
of action is still uncertain. However, it is established fact
that the technique works.
[0064] Another possibility is that nucleic acid is used
which on transcription produces a ribozyme, able to cut
nucleic acid at a specific site - thus also useful in influ-
encing gene expression. Background references for ri-
bozymes include Kashani-Sabet and Scanlon (1995).
Cancer Gene Therapy, 2, (3) 213-223, and Mercola and
Cohen (1995). Cancer Gene Therapy 2, (1) 47-59.
[0065] Thus, an antisense RNA or ribozyme directed
against toxin expression may be used to downregulate
production in non-target cells. Antisense RNA or ri-
bozyme production may be placed under control of a reg-
ulatable promoter so that such production can be down-
regulated in target cells (for instance by means of a p53
element as discussed above).
[0066] An approach to downregulating toxin produc-
tion in non-target cells (e.g. normal cells), and/or upreg-
ulating toxin production in target cells (e.g. tumour cells),
may be instead of or in addition to regulating antidote
production.
[0067] A further possibility is to use antisense RNA or
a ribozyme or other approach to downregulate antidote
production in target cells. Upregulating production in tar-
get cells of an antisense RNA or ribozyme against anti-
dote may be used to reduce levels of antidote in target
cells and thereby increase toxin activity in those cells.
[0068] Control of translation may be employed, for in-
stance by means of an internal ribosome entry sequence
(IRES) which may be controled using a RNA from yeast
(Das, et al. (1996), J. Virol., 70(3): 1624-32; Das, et al.
(1998), J. Virol., 72(7): 6638-47; Das, et al. (1998), Front
Biosci., 1: 3: D1241-52; Venkatosan, et al. (1999), Nucleic
Acids Res. 15: 27 (2): 562-72) or other that inhibit ribos-
ome assembly at the IRES.
[0069] In further embodiments, the killing system, toxin
and/or antidote or other inhibitor is provided to cells as
protein, for instance by direct injection into target cells,
such as in a tumour. In one embodiment, a carrier mol-
ecule is employed to facilitate uptake by cells, e.g. a 16
aa peptide sequence derived from the homeodomain of
Antennapedia (e.g. as sold under the name "Penetratin"),
which can be coupled to a peptide via a terminal Cys
residue. The "Penetratin" molecule and its properties are
described in WO 91/18981.. Another example is VP22
(Elliott and O’Hare (1999) Gene Ther 6(1): 149-51; Dilber
et al. (1999) Gene Ther 6(1): 12-21; Phelan et al. (1998)
Nat Biotechnol 16 (5) : 440-3).
[0070] Expression and purification of a toxin antidote
is straightforward. However, the toxic nature of a toxin
such as the Kid protein makes these more difficult to over-
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express and purify. However, appropriate strategies are
available or can be devised by those of ordinary skill in
the art. With reference to Kis/Kid, in absence of a Kid
resistant genetic background, the Kis antidote may be
co-expressed at the same time in the Kid overproducer
strains. The tight interaction that takes place between
both proteins to generate a neutralised complex allows
purification from a whole bacterial extract and separation
of the components afterwards by chaotropic denaturation
and further chromatographic purification and renatura-
tion of the toxic component. A bacterial one-or two- af-
finity chromatography-based approach has been de-
signed to purify Kid and Kid variants in high amounts and
a refolding protocol has been standardised to obtain ac-
tive, pure and concentrated preparations of the parD sys-
tem toxin. See the experiments described below. Such
an approach may be used to purify other toxic compo-
nents of different stability systems.
[0071] A composition comprising nucleic acid, protein
or cells according to the present invention may comprise
at least one additional component, such as a pharma-
ceutically acceptable diluent, vehicle or carrier, or a sol-
vent or carrier for delivery to the target organism, e.g.
plant. Nucleic acid, proteins, cells and compositions as-
disclosed herein may be used in a method of treatment
of the human or animal body by way of therapy, e.g. for
treatment of tumours, cancer, psoriasis, arteriosclerosis,
any other hyper-proliferative disorder, or other disorder.
Nucleic acid, protein, cells and compositions may also
be used in the manufacture of a medicament for such
treatment, and methods of treatment comprising admin-
istration of a medicament or pharmaceutical composition
to a eukaryote. Methods may comprise treating eukary-
otic cells with nucleic acid, protein, cells or compositions
as disclosed herein. The eukaryotic cells may be for ex-
ample any yeast, mammalian, plant, amphibian, avian,
fish or worm. Cells to be treated may be in vitro or in
culture , or may be comprised in a mammalian (e.g. hu-
man) body or plant or plant part (e.g. fruit, leaf, seed or
other propagule).
[0072] Compositions, cells and methods as described
herein may be used in methods in which expression of
a desired gene is targeted to desired cells, e.g. tumour
cells as opposed to non-tumour cells. Such methods may
be performed in vivo (e.g. by way of treatment of a human:
or animal body for therapeutic purposes), ex vivo (e.g.
on cells removed from a human or animal body, prior to
return of the cells to the body) or in vitro. Compositions
and cells may be used in the manufacture of a medica-
ment for treatment in which expression of a desired gene
is targetted to target cells (e.g. tumour cells). Nucleic acid
constructs may form part of a viral vector, for instance a
viral vector engineered to be suitable for administration
to an individual, such as a human, and preferably addi-
tionally tumour targetting.
[0073] Compositions provided may be administered to
individuals. Administration is preferably in a "therapeuti-
cally effective amount", this being sufficient to show ben-
efit to a patient. Such benefit may be at least amelioration
of at least one symptom. The actual amount adminis-
tered, and rate and time- course of administration, will
depend on the nature and-severity of what is being treat-
ed. Prescription of treatment, e.g. decisions on dosage
etc, is within the responsibility of general practitioners
and other medical doctors.
[0074] A composition may be administered alone or in
combination with other treatments, either simultaneously
or sequentially dependent upon the condition to be treat-
ed.
[0075] Pharmaceutical compositions according to the
present invention, and for use in accordance with the
present invention, may comprise, in addition to active
ingredient, a pharmaceutically acceptable excipient, car-
rier, buffer, stabiliser or other materials well known to
those skilled in the art. Such materials should be non-
toxic and should not interfere with the efficacy of the ac-
tive ingredient. The precise nature of the carrier or other
material will depend on the route of administration.
[0076] Experimental support for the present invention
will now be described by way of illustration. Various ad-
ditional aspects and embodiments of the present inven-
tion will be apparent to those skilled in the art.
[0077] "Comprising" herein is used with the meaning
of "including", that is permitting the presence of one or
more additional components or features.
EXAMPLE 1
Effect of expression of the parD system in Saccharomy-
ces cerevisiae
[0078] Several plasmids with different constitutive
and/or regulatable promoters were tested for their ability
to express both components of the parD system sepa-
rately in a controlled fashion. The results were similar
with all the promoters used. In addition to the promoters
used as described in detail in the following experiments,
the inventors performed experiments using the ADH5
promoter (constitutive; Mumberg, et al. (1995), Gene, 14:
156 (1) : 119-22) for kis and GAL10-CYC1 (galactose
activatable Guarente, et al. (1982), Proc. Natl. Acad. Sci.
USA, 79 (23) : 7410-4) for kid.
[0079] Antidote transcription in S. cerevisiae was con-
trolled by a promoter induced by Cu2+, while the toxin
transcription was controlled by a different promoter re-
pressed by methionine. With that purpose, the former
was cloned in a monocopy plasmid (ARSH4/CEN6 origin
of replication) and the latter was cloned in a multicopy
plasmid (2P origin of replication) that confer auxotrophy
for leucine and tryptophan respectively to a transfected
yeast (Figure 1).
[0080] Using a multicopy plasmid for the toxin expres-
sion has two advantages: first, it reduces the possibility
of selecting cells that have inactivated that protein by
mutation of its DNA, as each cell should have to inactivate
all the copies (10-30 molecules per haploid genome for
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a 2P origin harbouring plasmid) of the kid gene present
in each cell. Mutation of that gene in growth conditions
in which the system is inactivated by expression of the
antidote is unlikely as in that situation there is no selective
pressure for the cells in order to accumulate mutations.
This is verified by the fact that induction of the system
exerts a clear inhibitory effect over S. cerevisiae growth
(see below). Secondly, this approach showed that it is
also possible to regulate the amount of mRNA of each
component of the system by increasing or decreasing
the number of encoding DNA molecules for each one
(i.e. their copy number) without modifying the strength of
their promoters. This allows greater flexibility in the de-
sign of systems in eukaryotes, e.g. for yeast, anti-fungals
etc.
[0081] Different S. cerevisiae strains transfected with
kis+/kid+, kis+/ kid- or kis-/ kid- plasmids were grown in
liquid selective medium (-Leu/- Trp) in presence of
amounts of Cu2+ and methionine that maintain the parD
system in an inactivated state, before plating different
serial dilutions of these cultures in solid media with a
constant amount of methionine to give a constant expres-
sion of Kid (if any) in all the cases, but reduced concen-
trations of Cu2+ to decrease expression of its antidote
from plate to plate. Kis and kid harbouring cells were not
able to grow in media without Cu2+ and this effect is de-
creased as Cu2+ concentration increases until it reaches
approximately the same rate of growth as wild type (kis-/
kid-) cells. In contrast, both kis+/kid- and wild type (kis-/
kid-) cells were able to grow normally under all circum-
stances tested.
[0082] This experiment demonstrated that Kid and Kis
are active as a toxin and its antidote respectively in yeast
and that it is possible to regulate their activity (and thus
parD activation or inactivation) by means of transcription-
al control of its components in S. cerevisiae. It also pro-
vides indication that antidote expression alone has no
side effects and that the biological process inhibited by
the parD toxin is conserved among distantly evolved or-
ganisms.
EXAMPLE 2
Effect of the proteins of the parD system in Xenopus 
laevis
[0083] Two cell stage embryos from Xenopus laevis
were injected at the animal pole of one of the blastomers
either with Kis, Kid, both or none of them (buffer) and its
effects on subsequent cell divisions were followed along
time. Kid injected embryos only divided correctly in the
non-injected blastomer, while Kis-, Kis/ Kid- and buffer-
injected embryos blastomers progressed in all cases in
the same way as the non-injected ones along the embry-
onic development stages followed in the experiment (at
least until mid blastula transition, MBT).
[0084] This experiment further indicates that eukaryo-
tic cell cycle progression is severely affected by non- neu-
tralised Kid protein and suggests that this effect is not
exerted in any of its gap phases (G1 or G2) as they are
not present in the first stages of X. laevis development.
It also confirms that it affects a conserved biological proc-
ess among distant species and offers some clues related
to the possible mechanism of action of Kid (as X. laevis
embryonic replication does not require specific DNA se-
quences to initiate). The fact that progression through
the cell cycle of the non-injected blastomers in the Kid
injected embryos is not affected at all, together with the
lack of effects in both halves of the other injected embryos
(Kis, Kis/Kid and buffer), clearly indicates that the Kid
gene product is the responsible for that phenotype in eu-
karyotes and that the Kis gene product is responsible for
its neutralisation and has no side effects per se, when
used alone.
EXAMPLE 3
Effect of the parD system in human cells
[0085] The above results from yeast and amphibians
show that Kid is able to impede cell cycle progression
through the cell cycle in eukaryotes in a controlled fashion
and that it is possible in these organisms to substitute
the prokaryotic regulatory circuits that maintain the parD
system in a silent state under desired conditions by mod-
ulating transcription of both the antidote and the toxin
with different promoters.
[0086] For experiments in human cells a set of plas-
mids named pNATHA (for plasmids with Neutralisable
Activity that Triggers HeLa Apoptosis) was constructed.
Their mechanism of action is based in the observation
that in HeLa Tet Off cells a Cytomegalovirus Early pro-
moter (CMV Pr) maintains a constant level of transcrip-
tion of a reporter gene independently of the presence or
absence of Tetracyclin (or Doxycyclin) in the culture me-
dium. On the other hand, using the same cell line, a Tet-
racyclin regulatable promoter (Tet Pr) can decrease the
level of transcription of that reporter gene by more than
three orders of magnitude upon addition of the transcrip-
tional regulator. In the induced state (i.e. in absence of
Dox) Tet Pr directed transcription of the reporter gene is
almost two orders of magnitude higher than that of the
same reporter gene under control of the CMV Pr. In the
uninduced state (i.e. in the presence of Dox), the latter
transcribes almost two orders of magnitude more effi-
ciently than the former (Figure 2).
[0087] This transcriptional behaviour offers a window
that can be used to construct the pNATHA plasmids, in
which both kis and kid genes are contained in the same
DNA molecule, the antidote mRNA synthesis controlled
by the Tet repressible promoter and the toxin messenger
levels controlled by the CMV constitutive one. Both cas-
settes contained Kis and Kid were cloned in either direct
or inverted orientations (Figure 5). Toxin and antidote
can be cloned in a tail-to-tail or tail- to-head orientation
as convenient and to take advantage of transcriptional
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interference under appropriate control Both may be part
of the same transcriptional unit if an IRES is placed be-
tween the coding sequences.
[0088] Additional variants of both the antidote and the
toxin were tested in HeLa cells, after verifying their wild
type-like activity in vivo in E. coli. A Nuclear Localisation
Signal (NLS) was fused to Kid and Kis to test if it would
confer a more efficient effect (if any in human cells) both
impeding cell cycle progression or neutralising that im-
pedance, respectively.
[0089] All pNATHA were stably transfected in a HeLa
Tet Off cell line. The in vivo effect of both components of
the parD system on these cells was analysed before and
after addition of Doxycyclin to the different cultures. The
first observation of this set of experiments is that, again,
after induction of the system, cell growth rate is severely
inhibited in HeLa kis+/kid+ and nlskis+/kidnls+ cells. This
suggests two different things: first, that immediate trans-
port of the toxin into the nucleus (verified by confocal
microscopy of Kid immunostained samples) does not im-
pede its toxic effect, indicating the probable nuclear lo-
calisation of its cellular target(s); and second, that the
wild type components of the parD system are as active
as NLS-fused ones in HeLa cells, which indicates either
that entry into the nucleus is not impeded for the wild type
proteins, and/or that inactivation of the cellular target(s)
by Kid can occur in the cytosol. After one or two days
growing in presence of Doxycyclin, and up to ten days
of treatment, an induced state of parD is detectable, as
kis+/kid+ cells have increased doubling time, compared
to kis+/ kid- transfectants or to kis+/kid+ cells grown in
absence of Doxycyclin (Figure 4). It should be noted that
as only kis transcription is being modulated directly, while
maintaining constant level of kid, the rate of growth for
those kis+/kid+ stabilised transfectants is lower than that
of their kis+/kid-counterparts in the same conditions. This
could be due to a slight escape of the system at the level
of its neutralisation ability if kid transcription is not re-
duced selectively at the same time.
[0090] The results showed progressive reduction of
cell doublings of kis+/kid+ stable transfectants upon con-
tinued exposure to Doxycyclin (i.e. to non-neutralised
toxin). The inventors were interested in whether it would
be possible to provide a cytostatic and/or cytotoxic effect.
[0091] Percentage of dead cells was determined after
treatment with sub-lethal doses of Doxycyclin of the dif-
ferent stable transfectants analysed previously. As indi-
cated before, kis+/ kid- HeLa cells showed an exponential
growth rate along time in both presence and absence of
Doxycyclin. On the contrary, kis+/kid+ HeLa cells showed
an exponential cell growth rate only when antidote tran-
scription was maintained (i.e. in absence of Doxycyclin)
but not in the opposite case, in which they reduced con-
tinuously their number of doublings (Figure 5). It should
be noted though that growth rate was reduced for kis+/
kid- HeLa cells grown in presence of Doxycyclin com-
pared to that of the same stabilised cell line grown in its
absence. This effect may be due to long exposure to
Doxycyclin even at sub-lethal doses and, in any case, it
does not lead to cell death. When dead cells were count-
ed for all the samples, kis+/kid+ HeLa cells growing in
presence of Doxycyclin (i.e. in presence of non- neutral-
ised toxin) showed a 32% and 65% of dead cells at days
five and ten of treatment, respectively, while all the other
samples did not show more than 9% even upon ten days
of treatment (Figure 5). Annexin V (i.e. an early apoptotic
marker) staining of the different samples analysed, dem-
onstrates that the observed cell death in kis+/kid+ non-
neutralised HeLa cell line was due to activation of apop-
tosis (Figure 6).
MATERIALS AND METHODS
Saccharomyces cerevisiae
Plasmids
[0092] Oligonucleotides XholKis (5’CCGCTCGAGA-
TGCATACCACCCGACTG3, - SEQ ID NO. 2) and Kis-
Ncol (5’CATGCCATGGTCAGATTTCCTCCTGACCA-
G3’ - SEQ ID NO. 3) were used to amplify the kis coding
region by PCR from a mini- R1 derivative. The amplified
product was digested with Xhol and Ncol and cloned in
the plasmid pSAL1 to construct pSAL1Kis (Mascorro-
Gallardo, et al. (1996), Gene, 172(1): 169-70). In a similar
way, oligonucleotides ATGKid (5’ATGGAAAGAGG-
GGAAATCTG3’ - SEQ ID NO. 4) and KidEcoRI (5’CGG-
AATTCCCCATGTTCAAGTC3’ - SEQ ID NO. 5) were
used to amplify the kid coding region using the same
template and the product obtained was digested with
EcoRI and cloned in the plasmid p424Met25 (Mumberg,
et al. (1994), Nucleic Acids Res., 25: 22(25): 5767-8) di-
gested with SmaI and EcoRI to construct the plasmid
p424Met25Kid. This plasmid was amplified in a bacterial
strain that overproduces Kis at the same time to abolish
selection of inactivated mutants during the cloning proc-
ess.
In vivo assay
[0093] Saccharomyces cerevisiae strain W303α
(MAT α, ade2-1, trpi- 1, can1-100, leu2-3, 112, his3-11,
ura3, psi+) was transformed with plasmids pSALl and
p424Met25 (null), pSAL1Kis and p424Met25 (kis+/kid-)
and pSAL1Kis and p424Met25kid (kis+/kid+). These
cells were grown in selective medium supplemented with
500 PM of methionine and 200 PM of SO4Cu to maintain
the kis and kid promoters in an activated and repressed
state respectively. The cultures were allow to grow until
mid-log phase and then a 3 Pl drop of dilutions of each
culture containing 15000, 1500 or 150 cells was posed
in agar plates made of selective medium supplemented
with 200 PM of methionine to maintain a constant ex-
pression level of the kid gene and 0, 1, 5, 10, 20, 40, 80,
100 and 200 PM of SO4Cu to increase the expression
level of the kis gene. The plates were incubated 48 hours
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at 30°C and the growth rate of each culture was analysed
afterwards on each plate.
Xenopus laevis
Kis and Kid overproducers
MBPKis overproducer
[0094] Oligonucleotides ATGKis (5’ATGCATACCAC-
CCGACTG3’ - SEQ ID NO. 6) and KisEcoRI (5’TCG-
GAATTCAGATTTCCTCCTG3’ - SEQ ID NO. 7) were
used to amplify kis by PCR using a mini-R1 plasmid as
template. The amplified product was digested with EcoRI
and cloned in pMAL-c2 plasmid (Mumberg, et al. (1994),
Nucleic Acids Res., 25:22(25): 5767-8) between the
Xmnl and EcoRI sites to obtain the MBP- (Maltose Bind-
ing Protein) Kis overproducer.
HisKisKid overproducer
[0095] Oligonucleotides NdeIkid (5’ GGAATTCCA-
TATGCATACCACCCGACT3’ - SEQ ID NO. 8) and
kisBamH1 (5’CGGGATCCTCAAGTCAGAATAGT3,
-SEQ ID NO. 9) were used to amplify the coding regions
of kis and kid in tandem from a mini-R1 derivative. The
product of PCR was digested with NdeI and BamHI and
cloned in pET15b (Invitrogen) between these sites. The
resultant plasmid was disgested with NcoI and BamH1
and the DNA fragment codifying for Hiskiskid was purified
and subcloned between these same sites in pRG-recA-
NHis (Giraldo, et al. (1998), EMBO J., 3: 17 (15): 4511-
26).
Protein purification
MBPKis purification
[0096] Kis protein was purified as a fusion with the Mal-
tose Binding Protein (MBP). Escherichia coli strain DH5α
transformed with the plasmid pMBPKis was inoculated
in 2 L of LB medium plus ampicillin (100 Pg/ml) at 0.04
units of Abs600nm and grown with shaking at 37°C until
0.4 units of Abs600nm were reached. MBPKis expression
was induced then by addition of IPTG 100 PM to the
culture medium. Cells were grown for 4 hours at 37°C
and then pelleted in a GS3 rotor and resuspended in 10
ml lysis buffer (20 mM Tris- HC1 pH 8.0, 150 mM NaCl)
and frozen in liquid nitrogen. After thawing cells, 2 mg of
lysozyme was added to the suspension of cells and lysis
was completed by incubation at 37°C for about 10 min-
utes, with cooling on ice every 3 minutes. A soluble frac-
tion was obtained by addition of 40 ml of buffer 20 mM
Tris-HCl pH 8.0, 600 mM NaCl and centrifugation at 30
Krpm at 4°C during 45 min in a 65 Ti rotor. MBPKis protein
was purified by affinity chromatography through an amy-
lose resin (BioLabs) following the manufacturers instruc-
tions in buffer 20 mM HEPES pH 7.5, 100 mM KC1, 1
mM DTT and 10% of ethyleneglycol. MBPKis fractions
were pooled and purity and concentration of the protein
were determined by coomassie staining on a SDS- PAGE
gel and by spectrophotometric analysis, respectively.
Fractions were stored at -80°C.
Kid purification
[0097] Escherichia coli strains C600 or TG1 trans-
formed with the overproducer pRG∆HisKisKid were
grown in 2 L of LB medium plus ampicillin (100 Pg/ ml )
at 0.04 units of Abs600nm, and grown with shaking at 37°C
until 0.4 units of Abs600nm were reached. HisKis and Kid
expression was induced then by addition of 25 Pg/ml of
nalidixic acid to the culture medium. Cells were grown
for 4 hours at 37°C and then.pelleted in a GS3 rotor and
resuspended in 10 ml lysis buffer (20 mM Tris-HCl pH
8.0, 150 mM NaCl) and frozen in liquid nitrogen. After
thawing, 2 mg of lysozyme was added to the suspension
of cells and lysis was completed by incubation at 37°C.
A soluble fraction was obtained by addition of 40 ml of
buffer 20 mM Tris- HCl pH 8.0, 600 mM NaCl and cen-
trifugation at 30 Krpm at 4°C during 45 min in a 65 Ty
rotor. This soluble fraction was precipitated by addition
of 60% of ammonium sulfate and centrifugation at 40
Krpm at 4°C for 60 min. The precipitated fraction was
then resuspended in 1 ml of 20 mM Tris-HCl pH 7.5, 500
mM KCl) and dialysed against the same buffer to elimi-
nate the ammonium sulfate. The dialysed fraction was
loaded in a 5ml fast-flow chelating sepharose (Pharma-
cia) activated with Ni2+ and equilibrated with the dialysis
buffer in which the HisKis-Kid complex was retained. A
gradient of 0 to 6 M of guanidinium cloride (GnCl) in 20
mM Tris- HCl pH 7.5 was applied to the column and de-
naturation of the HisKis-Kid complex bound to the column
led to retention of HisKid and elution of Kid at 5.5 M of
the chaotropic agent. Denatured Kid can be stored at
-80°C until necessary. For renaturation, Kid was diluted
to 5 pmol/ Pl in 6 M GnCl, 150 mM CIK, 100 mM phosphate
buffer pH 6.5, 20 mM β-mercaptoethanol, 0.2 mM EDTA
and 1.2 % CHAPS and dialysed 5 times during 6 hours
at 4°C against 200 ml (per 6 ml of protein) of 100 mM
phosphate buffer pH 6.5, 150 mM KC1, 10 mM β-mer-
captoethanol, 0.1 mM DTT and 10 % ethyleneglycol. The
soluble and refolded protein was separated from the in-
soluble (denatured) one by centrifuging the mix at 40
Krpm for 60 min at 4°C in a 65 Ty rotor. The supernatant
was concentrated in centricon tubes (cut off 3 K) and
aliquoted after determining purity and concentration of
the protein by coomassie staining on a SDS-PAGE gel
and spectrophotometric analysis, respectively, and
stored at -80°C.
Embryo microinjections
[0098] MBPKis and Kid proteins were dialysed against
buffer 20 mM Tri-HCl pH 8.0, 50 mM Kcl and 2 Pl of
MBPKid (160 ng/Pl) and 2 Pl of MBPKis (720 ng/ Pl) were
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mixed with each other or with 2 Pl of dialysis buffer and
incubated on ice for 10 min. 50 nl of each mix (buffer,
Kis, Kid and Kis/Kid) were microinjected into dejellied two
cell embryos of Xenopus laevis at the animal pole of one
of their cells. Microinjected and non-injected embryos
were then incubated in 4% of ficoll 400 in MBS buffer at
18°C and allow to progress through embryonic develop-
ment until stage 8-9 (blastula) was reached in the case
of the non- injected controls (7-8 hours). Embryos were
then photographed and the effect of microinjections an-
alysed afterwards.
HeLa cells
Plasmids (pNATHAs)
[0099] Oligonucleotides EcoRIKis (5’ CGGAATTC-
ATGCATACTACCACCCGACTG3’ - SEQ ID NO. 10) or
EcoRINLSKis (5’ CGGAATTCATGGACAAGGTTCCTA-
AGAAGAAGAGGAAGGTTAGCAGCATGCATACCAC-
C CGACTGAAG3’ - SEQ ID NO. 11) and KisXbal
(5’CTCTAGATCAGATTTCCTCCTGACC3’ - SEQ ID
NO. 12) were used to amplify kis by PCR using a mini-
R1 plasmid as template. The amplified product was di-
gested with EcoRI and XbaI and cloned in pTRE plasmid
(Clontech) between EcoRI and Xbal sites to obtain the
pTREKis and pTRENLSKis plasmids, respectively. On
the other hand, oligonucleotides XholKid (5’CCGCTCG-
AGATGGAAAGAGGGGAAATCT3’ - SEQ ID NO. 13)
and KidEcoRI (SEQ ID NO. 5) were used to amplify kid
by PCR using a mini-R1 plasmid as template, and
EcoRIKid (5’CGGAATTCATGGAAAGAGGGGAAATC-
T3’ - SEQ ID NO. 14) and KidNLSXbal (5’GCTCTA-
GATCAAACCTTCCTCTTCTTCTTAGGAGGCCTGCT-
GCTAGTCAGAATAGTGGA CAGGCG3’ - SEQ ID NO.
15) were used with the same purpose to obtain an NL-
SKid gene by PCR using a mini-R1 plasmid as template.
These two PCR products were digested with XhoI and
EcoRI or EcoR1 and XbaI, respectively, and cloned be-
tween these sites in the plasmid pClneo (Promega) to
obtain the plasmids pClneoKid and pClneoKidNLS.
These kid+ plasmids were amplified in a bacterial strain
that overproduces Kis at the same time to abolish selec-
tion of inactivating mutants during the cloning process.
Fragment BsTXI-Smal was deleted from pClneoKid and
pClneoKidNLS to eliminate the neomycin resistance
gene. The resultant plasmids (pCIKid and pCIKidNLS)
were digested with BgIII and BamHI and treated with Kle-
now, and the fragment containing the kid or kidNLS genes
were purified and cloned in the pTRE and pTREKis vec-
tors digested with HindIII and treated with Klenow. For
each of these constructs both orientations were selected,
and plasmids pNATHA1 (kis+), pNATHA2 (kis+/kid+),
pNATHA 4 (NLSkis+) and pNATHA 8 (NLSkis+/kidNLS+)
were obtained both in kis-kid tail-to-tail (pNATHAi) and
tail-to-head (pNATHAd) orientations.
Selection of stable transfectants
[0100] 5 Pg of each pNATHA was mixed with 0.5 Pg
of pTKHyg plasmid and HeLa Tet-Off cell line (Clontech)
was transfected with these mixtures by the Lipofectamine
method (Gibco). Stable transfectants were selected in
DMEM medium suplemented with glutamax and 10% of
tetracyclin approved fetal bovine serum (Clontech) and
in the presence of 200 Pg/ml of neomycin (Sigma) and
200 Pg/ml of hygromycin (Clontech) (non- toxic medium;
NTM).
In vivo assays
Cell growth and death rate determination
[0101] HeLa Tet Off cells stably transfected with
pNATHAli+ and pNATHA2i+ were grown in NTM until
they reached aproximately 80% of confluency. They were
trypsinised and 5x10 pNATHAi1+ and 2x104 pNATHAi2+
stably transfected cells were transfered to 4 wells of a
six multiwell plate and grown for 24 hours in NTM. After
that, one of the wells per sample was trypsinised and
these cells pelleted and stained with trypan blue. Total
and trypan blue stained (dead) cells per well were count-
ed with a cytometer. Then, 0.1 Pg/ml of Doxycycline (Sig-
ma) was added to the rest of wells and cells were allowed
to grow in this toxic medium (TM) for 2, 5 and 10 days,
changing it each 4 days when necessary but retaining
the floating (dead and mitotic) cells each time that fresh
TM was added. Trypsinisation, trypan blue staining and
counting of cells was repeated for each sample to deter-
mine the total and dead number of cells per sample.
Annexin V staining
[0102] HeLa Tet Off cells stably transfected with
pNATHA1+ and pNATHA2+ were grown in NTM until
they reached aproximately 80% of confluency. They were
trypsinised and 104 pNATHAi1+ and 5X104 pNATHAi2+
stably transfected cells were transfered to four dishes
(two per sample) of 5 cm of diameter in which four poly-
lysine coated coverslips were placed. Cells were allowed
to settle down for 24 hours and then 0.1 Pg/ml of doxy-
cyclin was added to one of the dishes per sample. Cov-
erslips were taken out from the dishes before (day 0) and
2, 5 and 10 days after addition of doxycyclin to one of
them. Fresh medium was added each 4 days if neces-
sary. Samples growing on these coverslips were stained
with FITC-Annexin V (Clontech) as suggested by the
manufacturer, before fixing them, and DNA was stained
with propidium iodide and Hoeschts 33258. Analysis and
counting of annexin V positive cells was done by confocal
microscopy and total and apoptotic number of cells was
determined.
23 24 
EP 1 198 239 B1
14
5
10
15
20
25
30
35
40
45
50
55
Claims
1. A composition comprising:
(i) the ParD kid toxin and ParD kis antitoxin, or
(ii) nucleic acid encoding the ParD kid toxin and
ParD kis antitoxin,
for use in a therapeutic method of inhibiting cell pro-
liferation and/or cell cycle progression carried out on
a human or animal body, the method comprising pro-
viding within eukaryotic cells in the human or animal
body the toxin and antitoxin, under appropriate con-
trol for selective cell cycle inhibition and/or killing of
target cells.
2. A composition according to claim 1 wherein said tox-
in is to be provided within said cells by means of
nucleic acid encoding said toxin under control of ap-
propriate control elements for expression.
3. A composition according to any one of the preceding
claims, for use in the method comprising providing
to said cells said toxin and said antitoxin and con-
trolling activity of said antitoxin on said toxin to control
activity of said toxin on said cells.
4. A composition according to claim 3 wherein said an-
titoxin is to be provided within said cells by means
of nucleic acid encoding said antitoxin under control
of appropriate control elements for expression.
5. A composition according to claim 3 or claim 4 where-
in the selectivite cell cycle inhibition and/or killing is
effected by a combination of (i) up-regulation of toxin
production in target cells and (ii) down-regulation of
toxin production in non- target cells and/or neutrali-
sation of toxin activity in non- target cells.
6. A composition according to claim 5 wherein neutral-
isation of toxin activity in non-target cells is effected
by upregulation of antitoxin production in non-target
cells.
7. A composition according to any one of claims 3 to 6
wherein said target cells are tumour cells.
8. Use of a composition comprising: 
(i) the ParD kid toxin and ParD kis antitoxin, or
(ii) nucleic acid encoding the ParD kid toxin and
ParD kis antitoxin,
in the manufacture of a medicament composition ac-
cording to the composition of any one of claims 1 to
7 for treatment of tumours, cancer, psoriasis, arteri-
osclerosis or other hyper-proliferative disorder.
9. A method of inhibiting cell proliferation and/or cell
cycle progression, the method comprising providing
within eukaryotic cells the ParD kid toxin and ParD
kis antitoxin under appropriate control for selective
cell cycle inhibition and/or killing of target cells,
wherein the cells are in vitro and/or are plant cells.
10. A method according to claim 9 wherein said toxin is
provided within said cells by means of nucleic acid
encoding said toxin under control of appropriate con-
trol elements for expression.
11. A method of inhibiting cell proliferation and/or cell
cycle progression, the method comprising providing
within eukaryotic cells the ParD kid toxin and ParD
kis antitoxin, wherein the cells are in vitro and/or are
plant cells.
12. A method according to any one of claims 9 to 11
comprising providing to said cells the ParD kid toxin
and ParD kis antitoxin, and controlling activity of said
antitoxin on said toxin to control activity of said toxin
on said cells.
13. A method according to claim 12 wherein said anti-
toxin is provided within said cells by means of nucleic
acid encoding said antitoxin under control of appro-
priate control elements for expression.
14. A method according to claim 12 or claim 13 wherein
selectivity for expression of said toxin within target
cells is effected by a combination of (i) up- regulation
of toxin production in target cells and (ii) down-reg-
ulation of toxin production in non-target cells and/or
neutralisation of toxin activity in non-target cells.
15. A method according to claim 14 wherein neutralisa-
tion of toxin activity in non-target cells is effected by
upregulation of antitoxin production in non-target
cells.
16. A method according to any one of claims 12 to 14
wherein said target cells are tumour cells.
Patentansprüche
1. Zusammensetzung, umfassend
(i) ParD- kid-Toxin und ParD-kis- Antitoxin oder
(ii) für das ParD-kid-Toxin und parD- kis- Antito-
xin kodierende Nucleinsäure
zur Verwendung in einem therapeutischen Ver-
fahren zur Hemmung der Zellproliferation und/
oder Zellzyklusprogression, das auf einem
menschlichen oder tierischen Körper durchge-
führt wird, wobei das Verfahren die Bereitstel-
lung des Toxins und Antitoxins in eukaryoti-
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schen Zellen im menschlichen oder tierischen
Körper unter geeigneter Kontrolle zur selektiven
Zellzyklusinhibition und/oder Tötung der Tar-
getzellen umfasst.
2. Zusammensetzung nach Anspruch 1, worin das To-
xin in den Zellen durch Nucleinsäure, die für das To-
xin kodiert, unter der Kontrolle geeigneter Expressi-
onskontrollelemente bereitgestellt werden soll.
3. Zusammensetzung nach einem der vorangegange-
nen Ansprüche zur Verwendung im Verfahren, das
die Bereitstellung des Toxins und des Antitoxins für
diese Zellen sowie die Kontrolle der Aktivität des An-
titoxins auf dem Toxin umfasst, um die Aktivität des
Toxins auf diesen Zellen zu kontrollieren.
4. Zusammensetzung nach Anspruch 3, worin das An-
titoxin in diesen Zellen durch Nucleinsäure, die für
das Antitoxin kodiert, unter der Kontrolle geeigneter
Expressionskontrollelemente bereitgestellt werden
soll.
5. Zusammensetzung nach Anspruch 3 oder 4, worin
die selektive Zellzyklusinhibition und/oder Tötung
durch eine Kombination von (i) Hinaufregulierung
von Toxinproduktion in Targetzellen und (ii) Herab-
regulierung von Toxinproduktion in Nicht-Targetzel-
len und/oder Neutralisierung von Toxinaktivität in
Nicht-Targetzellen ausgeführt wird.
6. Zusammensetzung nach Anspruch 5, worin die Neu-
tralisierung von Toxinaktivität in Nicht-Targetzellen
durch Hinaufregulierung von Antitoxinproduktion in
Nicht-Targetzellen ausgeführt wird.
7. Zusammensetzung nach einem der Ansprüche 3 bis
6, worin die Targetzellen Tumorzellen sind.
8. Verwendung einer Zusammensetzung, die Folgen-
des umfasst:
(i) das ParD-kid-Toxin und ParD- kis- Antitoxin
oder
(ii) Nucleinsäure, die für das ParD-kid-Toxin und
ParD- kis- Antitoxin kodiert, 
zur Herstellung einer Arzneimittelzusammen-
setzung gemäß der Zusammensetzung aus ei-
nem der Ansprüche 1 bis 7 zur Behandlung von
Tumoren, Krebs, Psoriasis, Arteriosklerose
oder anderen hyperproliferativen Erkrankun-
gen.
9. Verfahren zur Hemmung der Zellproliferation und/
oder Zellzyklusprogression, wobei das Verfahren die
Bereitstellung des ParD-kid-Toxins und ParD-kis-
Antitoxins in eukaryotischen Zellen unter einer ge-
eigneten Kontrolle zur selektiven Zellzyklusinhibition
und/ oder Tötung von Targetzellen umfasst, worin die
Zellen in vitro sind und/oder Pflanzenzellen sind.
10. Verfahren nach Anspruch 9, worin das Toxin in die-
sen Zellen durch Nucleinsäure, die für das Toxin ko-
diert, unter der Kontrolle von geeigneten Expressi-
onskontrollelementen bereitgestellt wird.
11. Verfahren zur Hemmung von Zellproliferation und/
oder Zellzyklusprogression, wobei das Verfahren die
Bereitstellung des ParD-kid-Toxins und ParD-kis-
Antitoxins in eukaryotischen Zellen umfasst, worin
die Zellen in vitro sind und/oder Pflanzenzellen sind.
12. Verfahren nach einem der Ansprüche 9 bis 11, das
die Bereitstellung des ParD-kid-Toxins und ParD-
kis-Antitoxins für die Zellen und die Kontrolle der Ak-
tivität des Antitoxins auf dem Toxin zur Kontrolle der
Aktivität des Toxins auf den Zellen umfasst.
13. Verfahren nach Anspruch 12, worin das Antitoxin in
den Zellen durch Nucleinsäure, die für das Antitoxin
kodiert, unter der Kontrolle geeigneter Expressions-
kontrollelemente bereitgestellt wird.
14. Verfahren nach Anspruch 12 oder Anspruch 13, wor-
in die Selektivität für die Expression des Toxins in
Targetzellen durch eine Kombination von (i) Hinauf-
regulierung von Toxinproduktion in Targetzellen und
(ii) Herabregulierung von Toxinproduktion in Nicht-
Targetzellen und/ oder Neutralisierung von Toxinak-
tivität in Nicht- Targetzellen erreicht wird.
15. Verfahren nach Anspruch 14, worin die Neutralisie-
rung von Toxinaktivität in Nicht-Targetzellen durch
eine Hinaufregulierung von Antitoxinproduktion in
Nicht-Targetzellen erreicht wird.
16. Verfahren nach einem der Ansprüche 12 bis 14, wor-
in die Targetzellen Tumorzellen sind.
Revendications
1. Composition comprenant:
(i) la toxine ParD kid et l’anti-toxine Pard kis, ou
(ii) un acide nucléique codant la toxine ParD kid
et l’anti- toxine ParD kis,
à utiliser dans un procédé thérapeutique pour inhiber
la prolifération cellulaire et/ou la progression du cycle
cellulaire, appliqué à un corps humain ou animal, le
procédé comprenant les étapes consistant à fournir,
dans les cellules eucaryotes du corps humain ou ani-
mal, la toxine et l’anti-toxine, sous contrôle appro-
prié, pour une inhibition sélective du cycle cellulaire
et/ou pour tuer des cellules cibles.
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2. Composition selon la revendication 1 dans laquelle
ladite toxine doit être fournie dans lesdites cellules
au moyen d’un acide nucléique codant ladite toxine
sous le contrôle d’éléments de contrôle de l’expres-
sion appropriés.
3. Composition selon l’une quelconque des revendica-
tions précédentes, à utiliser dans le procédé com-
prenant les étapes consistant à fournir aux dites cel-
lules ladite toxine et ladite anti-toxine et à contrôler
l’activité de ladite anti-toxine sur ladite toxine pour
contrôler l’activité de ladite toxine sur lesdites cellu-
les.
4. Composition selon la revendication 3 dans laquelle
ladite anti- toxine doit être fournie dans lesdites cel-
lules au moyen d’un acide nucléique codant ladite
anti-toxine sous le contrôle d’éléments de contrôle
de l’expression appropriés.
5. Composition selon la revendication 3 ou la revendi-
cation 4 dans laquelle l’inhibition sélective du cycle
cellulaire et/ou l’élimination sont réalisées par une
combinaisons (i) d’une régulation à la hausse de la
production de toxine dans les cellules cibles et (ii)
une régulation à la baisse de la production de toxine
dans les cellules non cibles et/ou une neutralisation
de l’activité de la toxine dans les cellules non cibles.
6. Composition selon la revendication 5 dans laquelle
la neutralisation de l’activité de la toxine dans les
cellules non cibles est réalisée par une régulation à
la hausse de la production d’anti-toxine dans les cel-
lules non cibles.
7. Composition selon l’une quelconque des revendica-
tions 3 à 6 dans laquelle lesdites cellules cibles sont
des cellules tumorales.
8. Utilisation d’une composition comprenant:
(i) la toxine ParD kid et l’anti-toxine Pard kis, ou
(ii) un acide nucléique codant la toxine ParD kid
et
l’anti- toxine ParD kis,
pour la fabrication d’une composition médicamen-
teuse selon la composition de l’une quelconque des
revendications 1 à 7 pour le traitement de tumeurs,
de cancers, du psoriasis, de l’artériosclérose ou
d’autres maladies d’hyperprolifération.
9. Procédé pour inhiber la prolifération cellulaire et/ou
la progression du cycle cellulaire, le procédé com-
prenant les étapes consistant à fournir, dans des cel-
lules eucaryotes, la toxine ParD kid et l’anti-toxine
ParD kis sous contrôle approprié, pour une inhibition
sélective du cycle cellulaire et/ou pour tuer des cel-
lules cibles, les cellules cibles étant des cellules in
vitro et/ou étant des cellules végétales.
10. Procédé selon la revendication 9 dans lequel ladite
toxine est fournie dans lesdites cellules au moyen
d’un acide nucléique codant ladite toxine sous le
contrôle d’éléments de contrôle de l’expression ap-
propriés.
11. Procédé pour inhiber la prolifération cellulaire et/ou
la progression du cycle cellulaire, le procédé com-
prenant les étapes consistant à fournir, dans des cel-
lules eucaryotes, la toxine ParD kid et l’anti-toxine
ParD kis, les cellules étant des cellules in vitro et/ou
des cellules végétales.
12. Procédé selon l’une quelconque des revendications
9 à 11 comprenant les étapes consistant à fournir
aux dites cellules la toxine ParD kid et l’anti-toxine
ParD kis et à contrôler l’activité de ladite anti-toxine
sur ladite toxine pour contrôler l’activité de ladite toxi-
ne sur lesdites cellules.
13. Procédé selon la revendication 12 dans lequel ladite
anti-toxine est fournie dans lesdites cellules au
moyen d’un acide nucléique codant ladite anti- toxine
sous le contrôle d’éléments de contrôle de l’expres-
sion appropriés.
14. Procédé selon la revendication 12 ou la revendica-
tion 13 dans lequel la sélectivité pour l’expression
de ladite toxine dans les cellules cibles est obtenue
en combinant (i) une régulation à la hausse de la
production de toxine dans les cellules cibles et (ii)
une régulation à la baisse de la production de toxine
dans les cellules non cibles et/ou une neutralisation
de l’activité de la toxine dans les cellules non cibles.
15. Procédé selon la revendication 14 dans lequel la
neutralisation de l’activité de la toxine dans les cel-
lules non cibles est obtenue par régulation à la haus-
se de la production d’anti-toxine dans les cellules
non cibles.
16. Procédé selon l’une quelconque des revendications
12 à 14 dans lequel lesdites cellules cibles sont des
cellules tumorales.
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